<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "\\amrndhw017\ESMLogs\icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254130_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151553</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013032803</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>2</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130124</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130124</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013032803</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>59</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientweight>67</patientweight>
			<patientheight>160</patientheight>
			<patientsex>2</patientsex>
			<resultstestsprocedures>Blood work for diabetes (2012): normal</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Depression</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking desvenlafaxine</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking unspecified medication</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Arthritis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking celecoxib</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>General body pain</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking celecoxib</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pain</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>taking celecoxib</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>gets very weepy and cried real easy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Crying</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Crying</reactionmeddrapt>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Pristiq</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>21-992</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>50</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>50 mg, 1x/day</drugdosagetext>
				<drugdosageform>Prolonged-release tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Depression</drugindication>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>DESVENLAFAXINE SUCCINATE MONOHYDRATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Crying</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Crying</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CELEBREX</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Arthritis</drugindication>
				<activesubstance>
					<activesubstancename>CELECOXIB</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CELEBREX</medicinalproduct>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>General body pain</drugindication>
				<activesubstance>
					<activesubstancename>CELECOXIB</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CELEBREX</medicinalproduct>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<activesubstance>
					<activesubstancename>CELECOXIB</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a Non-Clinical study program Pfizer Helpful Answers from a contactable consumer. A 59-year-old White female consumer started taking desvenlafaxine (PRISTIQ) 50mg oral tablet once a day for depression on an unknown date. Relevant medical history included arthritis, body ache, pain, depression and diabetes which were ongoing during the events. Relevant concomitant medications included celecoxib (CELEBREX) for arthritis, body ache and pain and unspecified medication for diabetes and she was taking the concomitant medications during the event. She stopped taking desvenlafaxine as she could not afford. After stopping desvenlafaxine she "got very weepy" and "cried real easy". She restarted taking desvenlafaxine 50 mg once a day. Relevant lab data included blood work for diabetes done in 2012 and results were normal. At the time of the report she was taking desvenlafaxine. She had recovered from the above mentioned events on an unknown date.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
